

REMARKS

Claims 1-4, 6-15, 17-18 and 21-30 are pending in the application.

The examiner's claim rejections are overcome or they are traversed as set forth below.

I. THE ANTICIPATION REJECTIONS

The examiner rejected all pending claims for anticipation over two different prior art references. The examiner's rejections are traversed below.

A. The WO 00/78779 Anticipation Rejection

The examiner rejected claims 1-4, 6-15, 17-18 and 21-30 for anticipation by WO 00/78779.

As an initial matter, this rejection is identical to a rejection made by the examiner in the May 31, 2006 Office Action for this case which the examiner withdrew in a subsequent Office Action. All rejected claims are novel over the cited prior art for the same reasons given in Applicant's May 31, 2006 Office Action Reply. Some of those reasons are reiterated below.

The Applicant respectfully draws the Examiner's attention to the quotation from 35 U.S.C. §102 provided in the subject Office Action. The definition for anticipation under 102 stated that "the invention" was described in an application or patent. To be anticipated, all of the subject matter of a claim must be clearly set forth in a single reference. Claim 1 is novel at least because WO 00/78779 does not disclose administering a compound by intravenous bolus. Independent claim 17 recites administration of a specific compound in a manner that "causes at least a 2.5 fold increase in coronary blood flow that is achieved within about 1 minute from the administration of the A_{2A} receptor agonist". Claim 17 is novel at least because WO 00/78779 does not disclose this claim feature. The remaining claims are novel and patentable at least by virtue of their dependence upon independent claim 1 or 17.

B. The Glover et al Anticipation Rejection

The examiner rejected all claims 1-4, 6-15, 17-18 and 21-30 for anticipation by the Glover et al. Circulation Article. ("Glover").

The Glover et al. Article does not anticipate any application claims at least because it fails to disclose each of the following claim features:

- The specific compounds recited in independent claims 1 and 17. Glover discloses a compound called JMR-193 but does not disclose what the compound is.

- Glover does not disclose using a compound to treat a human. Instead, Glover discloses testing the compound in vitro and administering the compound to a dog.
- Glover does not disclose the claim 17 requirement that the recited at least 2.5 fold increase in coronary blood flow is achieved without about a minute from administration of the compound. Instead Glover discloses that the peak coronary blood flow is achieved 2.3 minutes post injection.

Independent claims 1 and 17 are novel for one or more of these reasons. Claims 2-4, 6-15, 18 and 21-20 are novel at least by virtue of their dependence upon independent claims 1 and 17.

CONCLUSION

Applicants submit that the claims are in condition for allowance. A Notice of Allowance is requested, and a prompt mailing thereof would be much appreciated. Should the Examiner have any questions, he is invited to contact the undersigned attorney at (312) 913-2123.

Respectfully submitted,

McDonnell Boehnen Hulbert & Berghoff LLP

Date: June 22, 2009

By: /A. Blair Hughes /
A. Blair Hughes
Reg. No. 32,901
(312) 913-2123